Loring Wolcott & Coolidge Fiduciary Advisors 13F: Cuts IDXX Stake by $1.2M
Key Points
- Loring Wolcott reduced its holdings in IDEXX Laboratories by 2,361 shares, bringing its total to 114,834 shares valued at approximately $59.97 million.
- As of October 25, 2026, IDXX shares were trading around $560.38, about equal to the closing price on the filing date.
- The stock has a target mean price of $698.00, indicating potential upside from its recent trading levels.
Get IDEXX Laboratories text alerts
We text you when insiders, Congress, analysts or big funds move on $IDXX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated IDEXX Laboratories, Inc. alert may contain errors. Disclosures
On October 23, 2026, Loring Wolcott & Coolidge Fiduciary Advisors trimmed its position in IDEXX Laboratories, Inc. (IDXX) by selling 2,361 shares.
IDXX
IDEXX Laboratories, Inc.
What Changed in Loring Wolcott & Coolidge's IDEXX Position
Loring Wolcott reduced its stake by 2,361 shares, resulting in a 2.01% decrease in its holdings. The firm now holds 114,834 shares of IDEXX Laboratories. This adjustment reflects a strategic decision within the firm, possibly indicating a shift in confidence or a reallocation of resources.
Other Institutional Activity in IDEXX
Other funds have also adjusted their positions in IDEXX Laboratories. William Blair Investment Management reduced its stake by 89,703 shares, leaving it with 351,621 shares valued at about $196.09 million. Fundsmith trimmed its holdings by 410,249 shares, bringing its total to 1,465,786 shares worth about $771.65 million. Meanwhile, BAMCO Inc. increased its stake by 343,347 shares, now holding 1,976,778 shares valued at approximately $1.11 billion.
IDEXX Laboratories, Inc. Stock Down 1.1%
As of October 25, 2026, IDEXX shares were trading around $560.38, which is about equal to the closing price on October 23. The stock is currently above its 50-day moving average by about 5.1% but below its 200-day moving average by 2.8%. It is also 27.2% below its 52-week high of $769.98.
Recent Earnings
IDEXX reported trailing twelve-month revenue of $4.55 billion and an EPS of $14.23. The company has shown a revenue growth of 9.7% year-over-year and a net margin of 25%. The next earnings report is scheduled for November 2, 2026.
Analysts Set New Price Targets
On August 5, 2026, both UBS and Citigroup maintained their Neutral rating on IDEXX, each with a price target of $670. Barclays, on August 11, 2026, maintained an Overweight rating but lowered its target from $800 to $710. JP Morgan reiterated its Overweight rating on October 16, 2026, with a new target of $750.
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops and distributes products for veterinary practices and water testing industries. The company operates through three segments: Companion Animal Group, Water Quality Products, and Livestock, Poultry and Dairy. This diverse portfolio supports its stable revenue growth and positions it well within the healthcare sector.
Bottom Line
Investors should watch for IDEXX's upcoming earnings report on November 2, 2026. Loring Wolcott's recent reduction in holdings signals a potential shift in strategy. Further institutional activity and analyst ratings will be key indicators to monitor for future movements in IDXX shares.
Related Filing Alerts
Source: Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing on $IDXX (Oct 23, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts